Capstone Therapeutics Corp
OTC:CAPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Smart Control Co Ltd
SZSE:001266
|
CN |
|
Masterflex SE
XETRA:MZX
|
DE |
Capstone Therapeutics Corp
Change in Working Capital
Capstone Therapeutics Corp
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Capstone Therapeutics Corp
OTC:CAPS
|
Change in Working Capital
$734k
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$2.4B
|
CAGR 3-Years
-109%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$3.9B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$10B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-86%
|
CAGR 10-Years
-30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
$532.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
Capstone Therapeutics Corp
Glance View
Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.
See Also
What is Capstone Therapeutics Corp's Change in Working Capital?
Change in Working Capital
734k
USD
Based on the financial report for Dec 31, 2019, Capstone Therapeutics Corp's Change in Working Capital amounts to 734k USD.
What is Capstone Therapeutics Corp's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
75%
Over the last year, the Change in Working Capital growth was 1 939%. The average annual Change in Working Capital growth rates for Capstone Therapeutics Corp have been 75% over the past three years .
